Media coverage about Qiagen N.V. (NASDAQ:QGEN) has trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Qiagen N.V. earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.213626839766 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Analytics for Quant Score Drive Upgrade of Qiagen NV (QGEN) to Buy – Investorplace.com (investorplace.com)
- QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women’s Health Genetic Screening (finance.yahoo.com)
- Initiating Research Reports on Services Equities — QIAGEN, Pinn – KTVN Channel 2 – Reno Tahoe Sparks News, Weather, Video (ktvn.com)
- Vanguard Sht Term Govt Bond ETF : Group Inc. Has $202.99 Million Stake in Qiagen N.V. (QGEN) (4-traders.com)
Shares of Qiagen N.V. (QGEN) opened at 33.52 on Wednesday. The stock has a market cap of $7.65 billion, a price-to-earnings ratio of 102.51 and a beta of 1.14. The firm has a 50-day moving average price of $32.93 and a 200-day moving average price of $32.53. Qiagen N.V. has a 12 month low of $24.86 and a 12 month high of $36.34.
Qiagen N.V. (NASDAQ:QGEN) last announced its earnings results on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The firm had revenue of $349.00 million for the quarter, compared to analyst estimates of $353.09 million. During the same quarter last year, the business earned $0.24 earnings per share. Qiagen N.V.’s revenue was up 4.4% compared to the same quarter last year. Equities analysts expect that Qiagen N.V. will post $1.21 EPS for the current fiscal year.
Several brokerages have recently weighed in on QGEN. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a report on Monday, July 31st. Barclays PLC restated an “overweight” rating and set a $37.00 target price (up from $33.00) on shares of Qiagen N.V. in a report on Monday, July 17th. Zacks Investment Research cut Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Monday, October 16th. BidaskClub cut Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, Independent Research GmbH upgraded Qiagen N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Qiagen N.V. presently has a consensus rating of “Hold” and a consensus price target of $33.28.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Qiagen N.V. (QGEN) Share Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2982137/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-qiagen-n-v-qgen-share-price.html.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.